Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting
Primary Care Diabetes · 2024-10 · 18 (5) · 511-517
DOI: 10.1016/j.pcd.2024.06.013 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Primary Care Diabetes, 2024-10. Verfasst von Lei Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, USA. Electronic address: lzlv@novonordisk.com. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Dipeptidyl-Peptidase IV Inhibitors, Medication Adherence. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk AS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, USA. Electronic address: lzlv@novonordisk.com.
- Merative, 100 Phoenix Dr Suite 200, Ann Arbor, MI 48108, USA.
- Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, USA.
- Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Förderung
- Novo Nordisk AS
Zitieren
APA
Lv, L., Brady, B. L., Xie, L., Guevarra, M., & Turchin, A. (2024). Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting. Primary Care Diabetes, 18(5), 511-517. https://doi.org/10.1016/j.pcd.2024.06.013
Vancouver
Lv L, Brady BL, Xie L, Guevarra M, Turchin A. Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting. Primary Care Diabetes. 2024;18(5):511-517. doi:10.1016/j.pcd.2024.06.013
BibTeX
@article{Lv2024,
author = {Lv, Lei and Brady, Brenna L and Xie, Lin and Guevarra, Mico and Turchin, Alexander},
title = {Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting},
journal = {Primary Care Diabetes},
year = {2024},
volume = {18},
number = {5},
pages = {511--517},
doi = {10.1016/j.pcd.2024.06.013}
}
EUVIMED